Dallas, Texas 07/16/2013 (Financialstrend) – The development stage bio pharmaceutical company with primary involvement in the development of new therapeutics for fighting cancer through the immune system, ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC), recently published a report to review the products in its pipeline. The report discusses various monoclonal antibodies and other immune therapies that are being developed by the company including ICT-140, ICT-107 and ICT-121.
ICT-140 is being developed to fight ovarian cancer and ICT-121 is designed to target the treatment of solid tumors. ICT-107 is currently being developed for the treatment of glioblastoma multiforme. The company reported net losses of $11.60 million for the last twelve months of operation and the price to cash ratio for the same period was calculated at 4.80. The return on equity for the pharmaceutical company was -99.10% and the return on assets was -61.90%. IMCU is currently planning to advance the pipeline of its products related to immune-based therapies to provide for advancements in the treatment of cancer. The recently released report will provide a basic source of information related to the portfolio of pipeline products of the company.
Intraday range was from a low price of $2.26 to a high price of $2.59. The share price of ImmunoCellular Therapeutics Ltd. (NYSEMKT:IMUC) closed for the day at $2.59, recording an increase of 15.11%. The price range of ImmunoCellular Therapeutics Holdings for the past 52 weeks was from a low $1.51 to a high of $3.58. The stock opened at the price of $2.32 on Monday with a market capitalization of $136.57 million and 52.73 million outstanding shares. With an institutional ownership of 17%, the trading volume for the day of ImmunoCellular Therapeutics Holdings was 2.50 million and the average trading volume was 782,561.00 shares.